Treatment of agnogenic myeloid metaplasia with danazol: A report of four cases

✍ Scribed by Lévy, V.; Bourgarit, A.; Delmer, A.; Legrand, O.; Baudard, M.; Rio, B.; Zittoun, R.

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 235 KB
• Volume: 53
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/(sici)1096-8652(199612)53:4<239::aid-ajh5>3.0.co;2-z

✦ Synopsis

Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400-600 mg/ day). Three of them became independent of red blood cell (RBC) transfusion, while the other had a slight reduction in RBC requirement. In addition, correction of thrombocytopenia and disappearance of splenomegaly were observed in 1 and 2 patients, respectively. No side effects were observed. In our experience, danazol appears effective and safe in the subset of patients with AMM whose disease is mainly characterized by bone-marrow failure. These data warrant further studies to evaluate this treatment and explore its mechanism of action.